James J. Curran, MD
Professor of Medicine
Department of Rheumatology
The University of Chicago Pritzker School of Medicine
Despite the availability of a variety of treatment options, many patients with psoriatic arthritis (PsA) continue to experience suboptimal outcomes. Recent research, however, has resulted in several newly approved and investigational agents that are likely to improve patient outcomes. This activity will examine recently approved and investigational therapies and their potential integration into treatment.
Rheumatologists, dermatologists, and other clinicians who treat patients with PsA.
Upon completion of this educational activity, the participant should be able to:
- Summarize recent data on emerging investigational therapies for PsA.
- Describe the optimal, evidence-based role of the PDE4 inhibitor apremilast in the treatment of PsA.
- Describe the optimal, evidence-based role of the IL-12/23 antagonist ustekinumab in the treatment of PsA.
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.
Dr. Curran has no relevant financial relationships with any commercial interests.
Mahira Zec Bonomo, University of Chicago, Director for CME, has nothing to disclose.
Lillian McVey, MCM Education medical writer, has nothing to disclose.
Kathleen Hines, MCM Education VP, Editorial Affairs, has nothing to disclose.
Terry Ann Glauser, MD, MPH, MCM Education VP, Medical Affairs, has nothing to disclose.
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and MCM Education. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses and other health care professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Commercial Support Statements
Supported by educational grants from AbbVie, Inc.; Celgene Corporation; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, The University of Chicago Pritzker School of Medicine, AbbVie, Inc., Celgene Corporation, or Janssen Biotech, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.